WO1995015331B1 - PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION - Google Patents

PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION

Info

Publication number
WO1995015331B1
WO1995015331B1 PCT/US1994/013947 US9413947W WO9515331B1 WO 1995015331 B1 WO1995015331 B1 WO 1995015331B1 US 9413947 W US9413947 W US 9413947W WO 9515331 B1 WO9515331 B1 WO 9515331B1
Authority
WO
WIPO (PCT)
Prior art keywords
alk
agent
protein
lymphoma
npm
Prior art date
Application number
PCT/US1994/013947
Other languages
English (en)
Other versions
WO1995015331A1 (fr
Filing date
Publication date
Priority claimed from US08/160,861 external-priority patent/US5529925A/en
Application filed filed Critical
Priority to EP95906601A priority Critical patent/EP0731806B2/fr
Priority to DE69433665T priority patent/DE69433665T3/de
Priority to AU15116/95A priority patent/AU679833B2/en
Priority to JP7515804A priority patent/JPH09512161A/ja
Publication of WO1995015331A1 publication Critical patent/WO1995015331A1/fr
Publication of WO1995015331B1 publication Critical patent/WO1995015331B1/fr

Links

Abstract

L'invention porte sur l'identification, et la détermination des séquences, de protéines fusionnées produites par translocation et présentes dans les cellules des lymphomes t(2;5). L'invention fournit des méthodes de détection et de traitement du lymphome t(2;5) utilisant les séquences susdites d'acides aminés ou d'acide nucléique de ces protéines fusionnées.
PCT/US1994/013947 1993-12-03 1994-12-05 PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION WO1995015331A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP95906601A EP0731806B2 (fr) 1993-12-03 1994-12-05 PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION
DE69433665T DE69433665T3 (de) 1993-12-03 1994-12-05 SPEZIFISCHE FUSIONSNUKLEINSÄUREN UND PROTEINE IN HUMANEN t(2;5)LYMPHOMEN, VERFAHREN ZU IHREM NACHWEIS UND IHRE VERWENDUNG
AU15116/95A AU679833B2 (en) 1993-12-03 1994-12-05 Specific fusion nucleic acids and proteins present in human t(2;5) lymphoma, methods of detection and uses thereof
JP7515804A JPH09512161A (ja) 1993-12-03 1994-12-05 ヒトｔ（２；５）リンパ腫に存在する特異的融合核酸及びタンパク質、それらの検出方法及び用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,861 US5529925A (en) 1993-12-03 1993-12-03 Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US08/160,861 1993-12-03

Publications (2)

Publication Number Publication Date
WO1995015331A1 WO1995015331A1 (fr) 1995-06-08
WO1995015331B1 true WO1995015331B1 (fr) 1995-06-22

Family

ID=22578775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/013947 WO1995015331A1 (fr) 1993-12-03 1994-12-05 PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION

Country Status (7)

Country Link
US (4) US5529925A (fr)
EP (1) EP0731806B2 (fr)
JP (1) JPH09512161A (fr)
AU (1) AU679833B2 (fr)
CA (1) CA2177957A1 (fr)
DE (1) DE69433665T3 (fr)
WO (1) WO1995015331A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US20030165931A1 (en) * 1998-03-11 2003-09-04 Bruno Tocque Qualitative differential screening
DE19610255B4 (de) * 1996-03-15 2004-11-04 Universität Heidelberg Verfahren zur Herstellung von Nukleinsäuresequenzen und Verfahren zum Nachweis von Translokationen zwischen Chromosomen
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
AU737190B2 (en) * 1996-12-06 2001-08-09 Niels Pallisgaard Detection of chromosomal abnormalities
US5994522A (en) * 1997-01-24 1999-11-30 Washington University BLNK proteins
US20030096255A1 (en) * 1997-02-19 2003-05-22 Felix Carolyn A. Methods and kits for analysis of chromosomal rearrangements associated with cancer
EP0878552A1 (fr) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Détection moléculaire d'aberration chromosomique
US6849400B1 (en) * 1997-07-23 2005-02-01 Gen-Probe Incorporated Methods for detecting and measuring spliced nucleic acids
CA2327542C (fr) * 1998-05-04 2011-11-22 Dako A/S Procede et sondes de detection d'aberrations chromosomiques
FR2798392B1 (fr) * 1999-09-13 2005-07-15 Exonhit Therapeutics Sa Marqueurs genetiques de la toxicite, preparation et utilisations
FR2798673B1 (fr) * 1999-09-16 2004-05-28 Exonhit Therapeutics Sa Methodes et compositions pour la detection d'evenements pathologiques
WO2001096394A2 (fr) * 2000-06-14 2001-12-20 Georgetown University Medical Center La pleiotrophine, recepteur d'un facteur de croissance, utilisable pour le traitement de troubles de nature proliferante, vasculaire et neurologique
US7329744B2 (en) * 2001-04-27 2008-02-12 St. Jude Children's Research Hospital Inc. Fusion genes associated with acute megakaryoblastoc leukemias
US7214488B2 (en) * 2001-07-03 2007-05-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services Detection of MECT1-MAML2 fusion products
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
CA2513044A1 (fr) * 2002-03-01 2004-08-05 Dyax Corp. Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques
US7461843B1 (en) * 2002-08-23 2008-12-09 Elixir Gaming Technologies, Inc. Automatic card shuffler
AU2003302986A1 (en) * 2002-12-13 2004-07-09 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
PT1454992E (pt) * 2003-03-07 2006-09-29 Ist Naz Stud Cura Dei Tumori Ensaio de quinase do linfoma anaplastico, reagentes e composicoes
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
ITRM20040534A1 (it) * 2004-10-29 2005-01-29 Brunangelo Falini Mutanti della proteina nucleofosmina (npm), sequenze geniche corrispondenti e relativi usi.
US8124351B2 (en) 2005-11-18 2012-02-28 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
AU2007351581B2 (en) * 2006-04-14 2011-12-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PL2450437T3 (pl) * 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
AU2012201154B2 (en) * 2006-04-14 2012-09-13 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CN101443361B (zh) * 2006-04-28 2015-08-19 德勒尼克斯治疗股份公司 与受体酪氨酸激酶alk的胞外域结合的抗体
WO2009045965A2 (fr) * 2007-10-01 2009-04-09 The Trustees Of The University Of Pennsylvania Stat5a et ses analogues fonctionnels suppresseurs de tumeur pour le traitement de tumeurs malignes exprimant npm/alk et d'autres kinases oncogènes
JP2011511949A (ja) * 2008-02-12 2011-04-14 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ
US8352194B1 (en) 2008-06-17 2013-01-08 University Of South Florida Method to identify cancer fusion genes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP2427575B1 (fr) 2009-05-07 2018-01-24 Veracyte, Inc. Méthodes pour le diagnostic d'affections thyroïdiennes
EP3133167B1 (fr) * 2009-05-15 2018-09-12 Insight Genetics, Inc. Procédés se rapportant à des fusions d'alk pour diagnostiquer le cancer
EP2435584B1 (fr) 2009-05-26 2016-07-13 Quest Diagnostics Investments Incorporated Procédés de détection de dérèglements de gènes
US20120202214A1 (en) * 2009-10-06 2012-08-09 Kazuya Omi Method for detecting fusion gene
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US8546552B2 (en) 2009-12-23 2013-10-01 Quest Diagnostics Investments Incorporated TMPRSS2 for the diagnosis of prostate disease
AU2015201135B2 (en) * 2010-04-20 2017-02-02 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
WO2011133625A1 (fr) * 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Hybridation in situ chromogène à deux couleurs
WO2012019132A2 (fr) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Kinase des lymphomes anaplasiques dans le cancer du rein
US20140315943A1 (en) 2011-05-24 2014-10-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
US8906885B2 (en) 2011-07-07 2014-12-09 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds
CA2853799A1 (fr) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Therapie anticancereuse utilisant une combinaison d'inhibiteurs de hsp 90 et d'inhibiteurs de topoisomerase i
EP2776025A1 (fr) 2011-11-02 2014-09-17 Synta Pharmaceuticals Corp. Polythérapie d'inhibiteurs de hsp 90 avec des agents contenant du platine
JP2014533299A (ja) 2011-11-14 2014-12-11 シンタ ファーマシューティカルズ コーポレーション Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法
HUE037856T2 (hu) 2012-04-18 2018-09-28 Cell Signaling Technology Inc EGFR és ROS1 rákban
WO2013170182A1 (fr) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Traitement d'un cancer au moyen d'un composé inhibiteur de hsp90
MX2015010791A (es) 2013-02-22 2015-11-26 Hoffmann La Roche Metodos para tratar el cancer y prevenir la resistencia a farmacos.
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US9284594B2 (en) * 2013-07-23 2016-03-15 The Regents Of The University Of Michigan Compositions and methods relating to fusion protein biomarkers
US10160993B2 (en) * 2014-03-21 2018-12-25 Purdue Research Foundation Tyrosine kinase biosensors and methods of use
EP3825421B1 (fr) 2014-03-25 2022-06-22 Quest Diagnostics Investments Incorporated Détection de fusions de gènes par expression différentielle intragénique (ide) à l'aide de seuils de cycle moyen
MA39972A (fr) 2014-05-13 2015-11-19 Choi Ha Soon Composés et compositions d'induction de la chondrogenèse
WO2015191667A1 (fr) * 2014-06-10 2015-12-17 Blueprint Medicines Corporation Fusions de pkn1
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3256161A1 (fr) 2015-02-09 2017-12-20 Synta Pharmaceuticals Corp. Polythérapie d'inhibiteurs de hsp90 et d'inhibiteurs de pd-1 pour traiter un cancer
GB2557818A (en) * 2015-09-25 2018-06-27 Veracyte Inc Methods and compositions that utilize transciptome sequencing data in machine learning-based classification
WO2018104908A2 (fr) * 2016-12-09 2018-06-14 Boreal Genomics, Inc. Ligature liée
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
WO1991005064A1 (fr) * 1989-10-02 1991-04-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Procede sensible servant a mesurer les transcriptions chimeriques de l'adn contenant des translocations
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma

Similar Documents

Publication Publication Date Title
WO1995015331B1 (fr) PROTEINES ET ACIDES NUCLEIQUES SPECIFIQUES FUSIONNES PRESENTS DANS LE LYMPHOME HUMAIN t(2;5), ET LEURS METHODES DE DETECTION ET D'UTILISATION
EP2060630A3 (fr) PCA3, gènes de PCA3, et procédés d'utilisation
EP1006182A3 (fr) Fragments polypeptidiques du facteur VIIIc, sondes et séquences de ADN correspondants et constructions de ADN
WO1996039429A3 (fr) Proteine serique produite exclusivement dans les adipocytes
WO1998049313A3 (fr) Caracterisation d'erhlichia granulocyte et methodes d'utilisation
EP2275818A3 (fr) Procédé de reconnaissance précoce améliorée de la séroconversion d'un anticorps orienté contre le virus de l'hépatite C
EP0753743A3 (fr) Analyse de la vitamine D
AU2002223044A1 (en) Kit and method for detecting the esm-1 protein
CA2317816A1 (fr) Procede de detection de peptides
CA2234416A1 (fr) Determination immunochimique d'analytes multivalents
ATE223491T1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
CA2366523A1 (fr) Procede d'analyse de la quantite de tissu adipeux intra-abdominal
AU2256197A (en) High affinity nucleic acid ligands of complement system proteins
WO2003038116A3 (fr) Facteurs de virulence de salmonella et leurs utilisations
WO2001067097A3 (fr) Nouveau procede d'analyse biologique
IL139272A0 (en) New peptide fragments for protein purification
GB2289125A (en) Methods of assaying data-repairing enzymes and their alkylated derivatives
WO2002072753A3 (fr) Peptides de thymidylate synthase se fixant a l'arnm de la thymidylate synthase
WO1999023228B1 (fr) Polypeptides et adn svph1-26
Sokolovsky et al. Exhaustive Proteolysis of Derivatives of Lysozyme
EP1143011A3 (fr) Méthode pour detécter des substances biologiquement actives
AU4624997A (en) Nematode proteins, dna sequences coding therefor, their specific antibodies and their use in identifying nematicidal active substances
TH43074A (th) โปรตีนเชื่อมกลูโคสดีไฮโดรจีเนส และการใช้ของมันในระบบการแสดงลักษณะ
CA2588614A1 (fr) Procede d'analyse de la quantite de tissu adipeux intra-abdominal
WO2002016574A3 (fr) Procede d'identification de peptides de fission specifique et utilisation de telles sequences peptidiques